References
- Zeller E. Influence of isonicotinic and hydrazide (INH) and 2-isonicotinyl-2-isoprophy hydrazide (IIH) on bacterial and mammalian enzymes. Experientia 1952; 8: 349–350
- Block R. The clinical effects of isoniazid and iproniazid in the treatment of pulmonary tuberculosis. Ann. Intern. Med. 1954; 40: 881–900
- Crane G. Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating disease. Psychiatr. Res. Rep. Am. Psychiat. Assoc. 1957; 8: 142–152
- Kline N. Clinical experience with iproniazid (Marsilid). J. Clin. Exp. Psychoparhol. 1958; 19(Suppl. 1)72–78
- Mielezarek J., Johnson J. Tranylcypromine. Lancet February 16, 1963; 388–389
- Le Gassicke J. Tranylcypromine. Lancer February 2, 1963; 270
- Le Gassicke J. The clinical state, sleep and amine metabolism of a tranylcypromine (Parnate) addict. Br. J. Psychiatry, Ill 1965; 357–364
- Pitt B. Withdrawal symptoms after stopping phenelzine. Br. Med. J. May 11, 1974; 332–333
- Shopsin B., Mine N. Monoamine oxidase inhibitors: Potential for drug abuse. Biol. Psychiatry 1976; 2: 451–456
- Ben-Aric O., George G. A case of tranylcypromine (Parnate) addiction. Br. J. Psychiatry 1979; 135: 273–274
- Griffin N., Draper R. J., Webb M. G. T. Addiction to tranylcypromine. Br. Med. J. 1981; 283: 346
- Westemeyer J. Addiction to tranylcypromine (Parnate): A case report. Am. J Drug Alcohol Abuse 1989; 15(3)345–350
- Swanson D., Weddige R., Morse R. Abuse of prescription drugs. Mayo Clin. Proc. 1973; 48: 359–367
- Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., rev. American Psychiatric Association, Washington, D.C. 1987
- Wyatt R., Karoum F., Suddath R., Hitri A. The role of dopamine in cocaine use and abuse. Psychiatr. Ann. 1988; 18(9)531–534